Brief: Sellas Life Sciences Expects 60 Mg Cohort To Be Analyzed In Q2

Sellas Life Sciences

09/01/2024 14:20

Jan 9 (Reuters) - Sellas Life Sciences Group Inc
 SLS.O :
    * SELLAS LIFE SCIENCES RECEIVES FDA FAST TRACK DESIGNATION
FOR
SLS009 FOR TREATMENT OF RELAPSED/REFRACTORY ACUTE MYELOID
LEUKEMIA AND PROVIDES UPDATED DATA FOR PHASE 2A STUDY OF SLS009
IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA PATIENTS
    * SELLAS LIFE SCIENCES GROUP INC-  EXPECTS TO REPORT
ADDITIONAL
DATA FROM FULLY ENROLLED 45 MG COHORT AND INITIAL DATA FROM 60
MG COHORT IN Q1 OF 2024
    * SELLAS LIFE SCIENCES GROUP INC- EXPECTS 60 MG COHORT TO BE
ANALYZED IN Q2 OF 2024

Source text for Eikon:  ID:nGNX9mGvR5 
Further company coverage:  SLS.O 

 ((Reuters.Briefs@thomsonreuters.com))